Upon completion of his doctorate in Biochemistry and Biophysics at the Iowa State University, USA, in 1994, he moved to Stanford University for postdoctoral training where he worked on the signaling pathway of MAPK pathway. Dr. Huang joined the faculty of Division of Molecular and Genomic Medicine at the National Health Research Institutes (NHRI) in Taiwan in 1998 where he was an Assistant Investigator and promoted to Associate Investigator. Currently, Dr. Huang is the Distinguished Professor and Associate Dean at the College of Pharmaceutical Sciences at National Yang Ming Chiao Tung University. His study has led to two repurposed drugs to enter clinical trials for lung adenocarcinoma patients at Taipei-veteran general hospital and National Taiwan University Hospital, Taiwan. Recently, he has established extracellular vesicles-based therapy for various applications.

Dr. Haiyan Xie is a Boya distinguished professor at Peking University. Her research is focused on biopharmaceuticals. She has been selected as a fellow of the Royal Society of Chemistry. She is a Council member of the Chinese Society for Biomaterials, and a member of other 8 scholar committees. She has published 118 papers in peer-reviewed journals including Nat. Biomed. Eng., Cell Rep. Med., Sci. Adv., and Nat. Commun.. She has applied for 14 authorized patents and has converted of 2 patents, one of which has been mass produced. She has won the First-Tier Award of the Natural Science Prize from Hubei Province and the Special-Tier Award of S&T Progress Prize from Tianjin City.

Dr. Han Wei Hou is an Associate Professor at the School of Mechanical and Aerospace Engineering (MAE), and Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University Singapore (NTU). He is also an Adjunct Principal Research Scientist at Tan Tock Seng Hospital (TTSH), and currently serves as the Assistant Chair (Students) at MAE. Dr. Hou received his BEng (First Class Hons) and PhD degree in Biomedical Engineering at the National University of Singapore in 2008 and 2012, respectively. Upon graduation, he did his postdoctoral training at Massachusetts Institute of Technology (USA), and subsequently joined LKCMedicine as the inaugural LKCMedicine Postdoctoral Fellow in 2014. He started his research group at NTU (BioMicroSystems Laboratory, www.hwhoulab.com) in 2018 and his research interests include microfluidics blood diagnostics, organ-on-chips, extracellular vesicles, and biomanufacturing. He has authored over 60 peer-reviewed journal publications and filed 15 patents/patent applications. His recent research awards and accolades include World's Top 2% Scientists (By Stanford University) (2023, 2024, 2025), International Academy of Medical and Biological Engineering (IAMBE) Early Career Award (2022), NTU College of Engineering Research – Young Faculty Special Mention (2022), and International Society for Advancement of Cytometry (ISAC) Innovators (2021).

Dr Ong is a Senior Consultant Ophthalmologist in the Corneal and External Diseases department of the Singapore National Eye Centre and the Deputy Clinical Director of the Singapore Eye Bank. He is an Assistant Professor in the SingHealth Duke-NUS Ophthalmology ＆ Visual Sciences Academic Clinical Programme.

Dr Ong has been conferred his PhD in ocular surface inflammation and scarring by the University College London. He has won awards from the Royal College of Ophthalmologists, the Association for Research in Vision and Ophthalmology, the Asia-Pacific Association of Cataract and Refractive Surgeons, and the Asia-Pacific Academy of Ophthalmology for his research interests, which span several different aspects of corneal and external eye diseases, corneal transplantation, and refractive surgery. Through competitive application, he has also been awarded, as principal investigator, research grants from various funding bodies including the National Medical Research Council (NMRC) Singapore. His research work incorporates basic science and clinical translation, including cell-based therapies for corneal diseases.

Dr. Hsiu-Jung Liao is an Assistant Professor at the Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University (NYCU), and a principal investigator in the Department of Medical Research at Far Eastern Memorial Hospital (FEMH), Taiwan. She received her academic training at National Taiwan University (NTU) and further research training at Academia Sinica and the University of Tokyo, where she developed strong expertise in regenerative biology, immunology, and translational biomedical research.Her research focuses on extracellular vesicle (EV) therapeutics, immunomodulation, and AI-driven peptide discovery for regenerative medicine. Dr. Liao’s work integrates stem cell biology, extracellular vesicle engineering, and immunology to develop next-generation biologics for degenerative diseases, particularly osteoarthritis. Her laboratory has pioneered the development of peptide-primed mesenchymal stem cell–derived extracellular vesicles that promote cartilage regeneration while modulating inflammatory and immune signaling pathways. In addition, her team has established scalable EV purification technologies, including the NanoEx™ platform, to support EV manufacturing and clinical translation. Dr. Liao has received several prestigious innovation awards, including the National Innovation Award and the Future Technology Award, recognizing her contributions to regenerative medicine and AI-assisted therapeutic development. She is frequently invited to present at international conferences on extracellular vesicles, regenerative medicine, and advanced biotherapeutics. Her long-term goal is to develop clinically translatable EV-based therapeutics and AI-enabled drug discovery platforms that integrate regenerative medicine and immunomodulation to address degenerative and inflammatory diseases.

Professor Hsueh-Chia Chang is the Bayer Professor of Chemical and Biomolecular Engineering at the University of Notre Dame. He has been at Notre Dame since 1987 and has served as the department chair and the director of the Center for Microfluidics and Nanofluidics. His research is in the area of micro/nanofluidics and diagnostics, particularly integrated devices for the isolation and characterization of exosomes and other nanocarriers. His research has resulted in 19 patented technologies, eight of them have been licensed by four startups: Cubed Laboratories, AgenDx, ImpeDx and Aopia Biosciences. Products developed from these IPs include CRDTM Botrytis Detection kit by CubedLabs and NanoExTM exosome purification technology by Aopia Bio. Professor Chang served as the Chief Scientific Advisor of FCubed LLC (predecessor of CubedLabs) for 4 years. He co-founded Aopia Bio in 2019 and currently serves as its interim CTO and Board member. Professor Chang has published more than 300 papers and has a Google h-index of 79. He is the co-author of a seminal book in microfluidics: "Electrokinetically Driven Microfluidics and Nanofluidics" by Cambridge University Press in 2009. Professor Chang founded a new journal, Biomicrofluidics of the American Institute of Physics, in 2006 and served for 12 years as its Chief Editor. More than 35 PhD and post-doc students from his laboratory have embarked on academic careers as tenure-track professors in all engineering and science disciplines over 5 continents (15 in the US), including Duke, Imperial, Johns Hopkins etc. They include a chancellor, a Provost, three Department Chairs, four endowed chairs and five NSF Career Awardees. Industrial alumni from his group hold manager/director positions at Merck, Gilead, Alcon, Genentech and other major biotech and world-leading microfluidic companies. Professor Chang is a fellow of APS, NAI and AIMBE. His microfluidics work has been recognized by the Frenkiel Award from APS, the Lifetime Achievement Award from AES and the 1st Source Bank Commercialization Award. He has also won the Notre Dame Provost Research Achievement Award and was recognized at half time during the 2024 game against Stanford.

Hyo-Il Jung is a Professor in the School of Mechanical Engineering at Yonsei University, South Korea. He received his Ph.D. in Physical Biochemistry from the University of Cambridge, United Kingdom. His research focuses on developing advanced bio-analytical systems for human healthcare, particularly microfluidic strategies for the isolation and enrichment of circulating biomarkers such as circulating tumor cells and extracellular vesicles. Recently, Professor Jung has expanded his research to include digital AI-based design of artificial exosomes and their autonomous manufacturing using physical AI, which now constitute one of his major research interests. He is also actively engaged in bridging academic research with industry. He has contributed to the founding of start-up companies and currently serves as a technical advisor to several diagnostics as well as therapeutics firms. Over his career, he has authored more than 150 peer-reviewed journal articles and holds over 90 patents, reflecting both scientific impact and translational potential. He has also taken on significant leadership roles in the scientific community. Professor Jung is the former President of the Korean Society for Extracellular Vesicles (KSEV) and the Korean Biochip Society (KBS). He is also a fellow of the the National Academy of Engineering of Korean (NAEK). Through his research, innovation, and leadership, he continues to contribute to the advancement of biochip technologies and precision healthcare.

Dr Jiao Jiao Li is a Senior Lecturer in Biomedical Engineering at University of Technology Sydney (UTS), and a Rebecca L Cooper Medical Research Foundation Al & Val Rosenstrauss Fellow. Her research in regenerative medicine focuses on developing combinational approaches including stem cells, extracellular vesicles, bioactive materials, and nanomaterials to treat chronic diseases, particularly bone and joint disorders. Recent recognitions of her research include 2024 Eureka Prize for Emerging Leader in Science, 2023 Metcalf Prize for Stem Cell Research, and 2022 Young Investigator Award from Tissue Engineering & Regenerative Medicine International Society (TERMIS). Professionally, she serves on the TERMIS-AP Council, Australian Research Council (ARC) Advisory Committee, Board of Australian Institute of Policy & Science (AIPS), and Biomedical College Board of Engineers Australia. Her editorial roles include Associate Editor of Cartilage, Editorial Advisory Board of ACS Biomaterials Science & Engineering, and International Editorial Board of Journal of Orthopaedic Translation.

Dr. Minh Le is an Associate Professor, Graduate Program Director and Director of the Engineered Extracellular Vesicles for Anti-Cancer Therapy (EVANTICA) program at the Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore. Previously, she received a Ph.D. degree from the Singapore-MIT Alliance and trained as a postdoctoral fellow at Boston Children’s Hospital. Her group has developed novel strategies to harness EVs from red blood cells and engineer EVs for targeted delivery. For this research, they have received multiple national and international awards. Dr. Le currently serves as a deputy/associate editor for the Journal of Extracellular Biology and Journal of Extracellular Vesicles.

Leslie Yeo is a Distinguished Professor of Chemical Engineering at RMIT University, Australia. Following his PhD from Imperial College London in 2002, for which he was awarded the Dudley Newitt prize, he undertook a postdoctoral stint at the University of Notre Dame USA, after which he commenced a faculty position at Monash University. He also held the Australian Research Council’s Australian Research Fellowship and Future Fellowship from 2009 to 2017. Dr Yeo was the recipient of the Young Tall Poppy Science Award ‘in recognition of the achievements of outstanding young researchers in the sciences including physical, biomedical, applied sciences, engineering and technology’, and several awards for excellence in research and innovation both at Monash and RMIT. He is co-author of the book Electrokinetically Driven Microfluidics & Nanofluidics, author of over 250 publications and 65 patent applications, Editor-in-Chief of Biomicrofluidics and an editorial board member of several journals.

Bioengineering and Nanotechnology, The University of Queensland. His research focuses on extracellular vesicle biology, nanotechnology, and liquid biopsy, with the aim of developing minimally invasive approaches for disease detection and monitoring. He leads a translational research program spanning extracellular vesicle diagnostics and therapeutics, with particular interests in brain cancer, neurotrauma, and other central nervous system disorders. His work integrates nanotechnology, single-vesicle analysis, and biomarker discovery to profile rare extracellular vesicle populations from blood and other biofluids.

I hold a BSc (Hons) from National University of Singapore, a PhD from SUNY at Buffalo and received postdoctoral training at Columbia University. For nearly three decades, I have led independent research groups across multiple institutions in Singapore, with a consistent focus on disease mechanisms and therapeutic development. My current research centers on extracellular vesicles (EVs), particularly MSC-derived EVs, exploring their production, characterization, and clinical applications. I was named a Clarivate Highly Cited Researcher (2021–2024) and received the 2023 ISEV Special Achievement Award for Stem Cell EV Research. As an inventor, I hold over 100 granted patents across 12 families and have founded three biotech start-ups, one of which completed a Phase 1 clinical trial using topical MSC-exosomes for psoriasis in 2022.

Sven Kreutel studied biology at the University of Hohenheim in Stuttgart, Germany. After his graduation in biology, he received his PhD in microbiology and protein biochemistry at the University of Hohenheim under Prof. Dr. Andreas Kuhn and Dr. Dorothee Kiefer working on the light sensing and signal transduction in photosynthetic bacteria. Since then he worked in different sales and sales manager positions within the life science industry from clinical research over biology to nanoparticle sciences. In 2021 he was appointed as CEO of the American subsidiary of Particle Metrix.

Wei Seong Toh, PhD, is a tenured Associate Professor and Research Director at the Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore (NUS). He holds joint appointments in Faculty of Dentistry and Department of Biomedical Engineering. He is also a Principal Investigator at the NUS Tissue Engineering Programme.

His research focuses on understanding the mechanisms for degeneration and developing multidisciplinary strategies for regeneration of tissues of the musculoskeletal system. His team first reported the therapeutic efficacy of small extracellular vesicles from mesenchymal stromal cells (MSCs) in joint repair. He has secured over SGD9M funding, delivered over 70 plenary/keynote/invited talks and authored over 100 journal publications, accumulating h-index 49 and over 25,000 citations (Google Scholar). He and his team have received over 50 research awards and honors, including the A*STAR International Fellowship Award, Young Scientist Award at the World Biomaterials Congress, and World’s Top 2% Scientists by Stanford University from 2020 to present. He currently serves as the Secretary of Society for Clinical Research and Translation of Extracellular Vesicles Singapore (SOCRATES). He is also an executive committee member of Asia-Pacific Societies for Extracellular Vesicles (APSEV), a member of International Society for Cell & Gene Therapy (ISCT) Exosomes Committee, a member of International Society for Extracellular Vesicles (ISEV) Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics, and a member of International Cartilage Regeneration & Joint Preservation Society (ICRS) Workgroup on Underrepresented Regions. He also serves in the organizing committee for many meetings, including Scientific Chair for the International Conference for Biomedical Engineering (ICBME) 2026, and International Organizing Committee member for ISEV 2027. He is an Associate Editor for Genes & Diseases.

Professor Wojciech Chrzanowski is the Head of the Pharmaceutical Sciences at Sydney Pharmacy School and leads Nano-Medical Innovations Group. He has established and leads the work of three key research laboratories/facilities: Nano-BioCharacterisation, Laboratory for non-animal models, and BioNanoTechnology Facility in the Faculty of Medicine and Health. His facilities house unique instrumentation for the analysis of extracellular vehicles, such as exosomes and microvesicles. These nanoscale particles are involved in cell-to-cell communication and have enormous potential for drug delivery, diagnostics, and therapeutics. Professor Chrzanowski has made significant contributions to the understanding of the biophysical and biochemical properties of extracellular vehicles, as well as their interactions with cells, tissues and biomaterials.

Professor Chrzanowski has authored more than 200 peer-reviewed publications, which have been cited over 8,000 times. He has also received 16 international and national awards and prizes for his excellence and innovation in extracellular vesicle science and characterisation. Some of his notable recognitions include the 2019 Barry Inglis Medal from the National Measurement Institute, the 2018 Vice Chancellor’s Award for Excellence in Research and Education, the 2018 Best Presentation Award from the International Society for Extracellular Vesicles and the 2018 Outstanding Paper Award from the Royal Society of Chemistry.

Dr. Yichun Wang is the Keating-Crawford Collegiate Professor of Biomolecular Engineering and an Assistant Professor in Chemical and Biomolecular Engineering at the University of Notre Dame. Her laboratory advances multiscale material–bio interactions to create next-generation therapeutic and diagnostic platforms, with an emphasis on engineered carbon nanostructures, therapeutic extracellular vesicles, and physiologically relevant 3D biomimetic culture systems for high-content/high-throughput screening and scalable biomanufacturing. Dr. Wang’s work has been recognized with multiple honors, including the NSF CAREER Award, NIH Maximizing Investigators’ Research Award (MIRA), the ACS PMSE Early Investigator Award, the BMES Cellular and Molecular Bioengineering Rising Star Award, and selection as a Biomaterials Science Emerging Investigator. She also serves as an editor for the section “Applied Biomaterials and Biotechnologies” of Chemical Engineering Journal, as well as a standing member of the NIH Innovations in Nanosystems and Nanotechnology (INN) Study Section.

Dr Yiyao Huang is a researcher in the Department of Laboratory Medicine at Nanfang Hospital, Southern Medical University. She received her MD and PhD from Southern Medical University and completed her postdoctoral training at the Johns Hopkins University School of Medicine. Dr. Huang currently serves as a Member At Large of the International Society for Extracellular Vesicles (ISEV), a member of its Solid Tissue Task Force, and a Secretary Member of the Chinese Society for Extracellular Vesicles (CSEV). She is also a board reviewer for the Journal of Extracellular Vesicles. Her research focuses on EV-based biomarkers in neurological and infectious diseases and has been published in high-impact journals including Science Advances, Journal of Extracellular Vesicles, Aging Cell, and The Journal of Infectious Diseases, etc. Her EV-related work has been cited over 10,000 times, with an H-index of 17.